skepinone-L: a dibenzosuberone-type p38 MAPK inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 45279963 |
| CHEMBL ID | 2152944 |
| SCHEMBL ID | 2686103 |
| MeSH ID | M0573970 |
| Synonym |
|---|
| 2-(2,4-difluorophenylamino)-7-[2r-,3-dihydroxypropoxy]-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one |
| 3ff , |
| 2-[(2,4-difluorophenyl)amino]-7-{[(2r)-2,3-dihydroxypropyl]oxy}-10,11-dihydro-5h-dibenzo[a,d][7]annulen-5-one |
| bdbm50392175 |
| CHEMBL2152944 , |
| HY-15300 |
| skepinone-l |
| CS-0941 |
| S7214 |
| 1221485-83-1 |
| 3QUE |
| (r)-2-((2,4-difluorophenyl)amino)-7-(2,3-dihydroxypropoxy)-10,11-dihydro-5h-dibenzo[a,d][7]annulen-5-one |
| 5h-dibenzo[a,d]cyclohepten-5-one, 2-[(2,4-difluorophenyl)amino]-7-[(2r)-2,3-dihydroxypropoxy]-10,11-dihydro- |
| SCHEMBL2686103 |
| skepinone l |
| 2-(2,4-difluoroanilino)-7-[(2r)-2,3-dihydroxypropoxy]-10,11-dihydro-5h-dibenzo[a,d][7]annulen-5-one |
| DTXSID30669907 |
| AKOS027422745 |
| cbs3830 |
| SW219942-1 |
| BCP04105 |
| 2-[(2,4-difluorophenyl)amino]-7-[(2r)-2,3-dihydroxypropoxy]-10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5-one |
| AC-35955 |
| EX-A2161 |
| 13-(2,4-difluoroanilino)-5-[(2r)-2,3-dihydroxypropoxy]tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-one |
| CCG-268943 |
| Q27453778 |
| A891204 |
| AS-79383 |
| Z2235802136 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " IL-1β levels significantly reduced at 4 d and 14 d in both dosage groups." | ( Anti-inflammatory and anti-proliferative effects of CBS3830 in arterialized vein grafts in rats. Abendroth, DK; Ge, JJ; Liu, YZ; Pan, FM; Zhao, ZW; Zhou, ZC, 2014) | 0.4 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Heat shock protein beta-1 | Homo sapiens (human) | IC50 (µMol) | 0.0250 | 0.0250 | 0.0992 | 0.2000 | AID1792170 |
| Cholesteryl ester transfer protein | Homo sapiens (human) | IC50 (µMol) | 0.0050 | 0.0030 | 0.2169 | 4.1000 | AID691521 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 3.7111 | 0.0000 | 0.3855 | 10.0000 | AID1914141 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.1724 | 0.0003 | 0.7693 | 10.0000 | AID1914142 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 10.0000 | 0.0002 | 1.1115 | 8.0280 | AID1914143 |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | IC50 (µMol) | 0.0351 | 0.0007 | 0.4754 | 6.3000 | AID1792157; AID1912759; AID1912932 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 (µMol) | 0.0091 | 0.0001 | 0.7266 | 7.8000 | AID1792156; AID1792169; AID1820047; AID1912758; AID1912931; AID1913187; AID691521; AID721305 |
| Sigma intracellular receptor 2 | Homo sapiens (human) | Ki | 3.3580 | 0.0001 | 0.8360 | 4.6005 | AID1914146 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Mitogen-activated protein kinase 14 | Homo sapiens (human) | Kd | 0.0015 | 0.0015 | 0.0015 | 0.0015 | AID977611 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1657791 | Inhibition of p38alpha MAPK (unknown origin) assessed as target residence time using ATF2 as substrate preincubated for 1 hr followed by jump dilution in presence of substrate and measured every 3 mins for 4 hrs by TR-FRET assay | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Bioisosteric Replacement of Arylamide-Linked Spine Residues with |
| AID1899344 | Pro-proliferative activity in Wistar rat cardiac cells from P6 late postnatal developmental time points assessed as effect on cell number by measuring alphaAct/Ki67 cardiomyocyte nuclei at at 0.33 to 10 uM by DAPI analysis | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2 | High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation. |
| AID1899312 | Inhibition of P38betaMAPK (unknown origin) relative to control | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2 | High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation. |
| AID691523 | Inhibition of p38alpha-dependent TNFalpha production in human whole blood | 2012 | Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12 | Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase. |
| AID721305 | Inhibition of p38alpha MAP kinase (unknown origin) by ELISA | 2013 | Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1 | Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity. |
| AID1820047 | Inhibition of human p38 MAPK alpha | |||
| AID721304 | Inhibition of p38alpha MAP kinase in whole blood (unknown origin) assessed as lipopolysaccharide-stimulated TNF-alpha release by ELISA | 2013 | Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1 | Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity. |
| AID691521 | Inhibition of p38alpha by immunosorbent based kinase assay | 2012 | Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12 | Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase. |
| AID1899343 | Pro-proliferative activity in Wistar rat cardiac cells from P1 early postnatal developmental time points assessed as effect on cell number by measuring alphaAct/Ki67 cardiomyocyte nuclei at at 0.33 to 10 uM by DAPI analysis | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2 | High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation. |
| AID1899303 | Inhibition of P38alphaMAPK (unknown origin) relative to control | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2 | High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2011 | Nature chemical biology, Dec-25, Volume: 8, Issue:2 | Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (76.47) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.26) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||